The Liposome Co. Inc. responded to the failure of its Ventus C-53 liposomal prostaglandin in acute respiratory distress syndrome by announcing a restructuring designed to focus the company on its oncology programs.

On the heels of the Ventus setback in a Phase III trial (see BioCentury Extra June 26), the restructuring announced last week will cut 130-135 positions - 110 of which are filled - resulting in a 25 percent reduction in LIPO's total work force from more than 400 people. The company said it did not plan to cut any of its 40-person sales force or basic research positions, but would consolidate manufacturing, clinical development and administration.